KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Total Non-Current Liabilities (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 13 years of Total Non-Current Liabilities data on record, last reported at $2.4 billion in Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities rose 26.9% year-over-year to $2.4 billion; the TTM value through Sep 2025 reached $2.4 billion, up 26.9%, while the annual FY2024 figure was $2.4 billion, 13.1% up from the prior year.
  • Total Non-Current Liabilities reached $2.4 billion in Q3 2025 per IONS's latest filing, up from $2.3 billion in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $2.6 billion in Q3 2023 and bottomed at $1.8 billion in Q4 2021.
  • Average Total Non-Current Liabilities over 5 years is $2.1 billion, with a median of $2.1 billion recorded in 2023.
  • The widest YoY moves for Total Non-Current Liabilities: up 28.1% in 2024, down 26.82% in 2024.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $1.8 billion in 2021, then rose by 6.98% to $2.0 billion in 2022, then increased by 6.56% to $2.1 billion in 2023, then increased by 13.1% to $2.4 billion in 2024, then rose by 0.97% to $2.4 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $2.4 billion in Q3 2025, $2.3 billion in Q2 2025, and $2.3 billion in Q1 2025.